| abstract |
The application relates to modified blood coagulation factor, sequences encoding such modified factors, processes for their production, and related pharmaceutical compositions comprising such factors and their uses. More specifically, the application relates to mutations in the human FVII EGF-1 domain, wherein said mutations were analyzed for clotting activity, amidolytic activity and affinity of binding to full-length, relipidated human TF by competitive ELISA. |